iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 392,254 shares traded hands during trading, an increase of 170% from the previous session’s volume of 145,092 shares.The stock last traded at $102.78 and had previously closed at $101.24.
iShares U.S. Pharmaceuticals ETF Price Performance
The stock has a fifty day moving average of $97.38 and a 200 day moving average of $91.25. The firm has a market capitalization of $1.64 billion, a P/E ratio of 17.75 and a beta of 0.48.
Institutional Investors Weigh In On iShares U.S. Pharmaceuticals ETF
Hedge funds have recently made changes to their positions in the business. EFG International AG bought a new position in iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at about $38,000. O Shaughnessy Asset Management LLC increased its holdings in iShares U.S. Pharmaceuticals ETF by 35.0% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 463 shares of the company’s stock worth $39,000 after buying an additional 120 shares during the last quarter. Assetmark Inc. raised its position in iShares U.S. Pharmaceuticals ETF by 203.9% in the fourth quarter. Assetmark Inc. now owns 465 shares of the company’s stock worth $39,000 after acquiring an additional 312 shares during the period. Blueline Advisors LLC bought a new stake in iShares U.S. Pharmaceuticals ETF in the fourth quarter worth about $41,000. Finally, Accent Capital Management LLC purchased a new position in iShares U.S. Pharmaceuticals ETF in the fourth quarter valued at about $42,000.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Further Reading
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
- 3 Stocks That Prove the AI Trade Isn’t Over, It Moved
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
- 3 Stocks Taking Very Different Routes Through the Summer Rally
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
